+

WO2003047571A3 - Utilisation d'un inhibiteur kmo pour realiser une preparation pharmaceutique - Google Patents

Utilisation d'un inhibiteur kmo pour realiser une preparation pharmaceutique Download PDF

Info

Publication number
WO2003047571A3
WO2003047571A3 PCT/DE2002/004309 DE0204309W WO03047571A3 WO 2003047571 A3 WO2003047571 A3 WO 2003047571A3 DE 0204309 W DE0204309 W DE 0204309W WO 03047571 A3 WO03047571 A3 WO 03047571A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
pharmaceutical composition
kmo
kmo inhibitor
inhibitor
Prior art date
Application number
PCT/DE2002/004309
Other languages
German (de)
English (en)
Other versions
WO2003047571A2 (fr
Inventor
Andreas Rump
Original Assignee
Metagen Pharmaceuticals Gmbh
Andreas Rump
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Pharmaceuticals Gmbh, Andreas Rump filed Critical Metagen Pharmaceuticals Gmbh
Priority to AU2002351693A priority Critical patent/AU2002351693A1/en
Publication of WO2003047571A2 publication Critical patent/WO2003047571A2/fr
Publication of WO2003047571A3 publication Critical patent/WO2003047571A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un inhibiteur KMO pour réaliser une préparation pharmaceutique destinée au traitement de maladies cancéreuses, ainsi que l'utilisation d'une substance se liant au KMO pour réaliser une préparation pharmaceutique servant à la détection de cellules tumorales.
PCT/DE2002/004309 2001-11-28 2002-11-20 Utilisation d'un inhibiteur kmo pour realiser une preparation pharmaceutique WO2003047571A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002351693A AU2002351693A1 (en) 2001-11-28 2002-11-20 Use of a kmo inhibitor for producing a pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159215A DE10159215A1 (de) 2001-11-28 2001-11-28 Verwendung eines KMO-Inhibitors zur Herstellung einer pharmazeutischen Zusammensetzung
DE10159215.9 2001-11-28

Publications (2)

Publication Number Publication Date
WO2003047571A2 WO2003047571A2 (fr) 2003-06-12
WO2003047571A3 true WO2003047571A3 (fr) 2003-10-02

Family

ID=7707802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004309 WO2003047571A2 (fr) 2001-11-28 2002-11-20 Utilisation d'un inhibiteur kmo pour realiser une preparation pharmaceutique

Country Status (3)

Country Link
AU (1) AU2002351693A1 (fr)
DE (1) DE10159215A1 (fr)
WO (1) WO2003047571A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
WO2016193499A1 (fr) * 2015-06-05 2016-12-08 Immusmol Sas Anticorps immunomodulateur ou agent immunothérapeutique qui augmente et/ou reproduit la kynurénine, et combinaison éventuelle de ceux-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028167A1 (fr) * 1995-03-14 1996-09-19 Shaskan Edward G Compositions contenant de la nicotinylalanine et un inhibiteur de la conjugaison de la glycine ou de la vitamine b6
CH689327A5 (de) * 1995-01-23 1999-02-26 Josef Waller Pharmazeutisches Präparat für die Behandlung von Krebs, mindestens enthaltend Thymin als eine der Wirksubstanzen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689327A5 (de) * 1995-01-23 1999-02-26 Josef Waller Pharmazeutisches Präparat für die Behandlung von Krebs, mindestens enthaltend Thymin als eine der Wirksubstanzen
WO1996028167A1 (fr) * 1995-03-14 1996-09-19 Shaskan Edward G Compositions contenant de la nicotinylalanine et un inhibiteur de la conjugaison de la glycine ou de la vitamine b6

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MELICHAR, BOHUSLAV ET AL: "Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines", CLINICAL CANCER RESEARCH (1998), 4(12), 3069-3076, XP001098954 *
STONE T W: "KYNURENINES IN THE CNS: FROM ENDOGENOUS OBSCURITY TO THERAPEUTIC IMPORTANCE", PROGRESS IN NEUROBIOLOGY, PERGAMON PRESS, GB, vol. 64, no. 2, June 2001 (2001-06-01), pages 185 - 218, XP001007960, ISSN: 0301-0082 *

Also Published As

Publication number Publication date
AU2002351693A1 (en) 2003-06-17
DE10159215A1 (de) 2003-06-12
WO2003047571A2 (fr) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2003080582A3 (fr) Derives de fredericamycine
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
SG116507A1 (en) Pharmaceutical dosage form and method of making.
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003068157A3 (fr) Inhibiteurs de kinase et leurs procedes d'utilisation
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003047571A3 (fr) Utilisation d'un inhibiteur kmo pour realiser une preparation pharmaceutique
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003256157A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
WO1999056697A3 (fr) Composition pharmaceutique
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载